SLC5A2 and chronic kidney disease: The approval of disease‐specific agents—sparsentan (dual ET/angiotensin inhibition), nefecon (targeted mucosal immunomodulation), and iptacopan (complement blockade)—alongside repurposed CKD therapies (e.g., SGLT2 inhibitors) enables synergistic combinations for complete remission.